A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies

Trial Profile

A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Cord blood stem cell therapy (Primary)
  • Indications Haematological malignancies
  • Focus Registrational; Therapeutic Use
  • Sponsors Gamida-Cell
  • Most Recent Events

    • 18 Jun 2017 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.
    • 18 Jun 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2018.
    • 28 Feb 2017 According to a Gamida Cell media release, the first patient has been transplanted in this trial of NiCord, which is being developed as a cure for patients with blood cancer who do not have a fully matched donor required for bone marrow transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top